Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Absci Announces Research Collaboration with Merck; Absci Eligible to Receive up to $610M in Upfront Fees and Milestone Payments Plus Royalties

Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced that it has entered into a research collaboration with Merck (known as MSD outside the United States and Canada), using Absci's AI-powered In

ABSI